Free Trial
→ Musk's shopping list: batteries ✓ solar ✓ data ✓ power ___ (From Behind the Markets) (Ad)tc pixel
NASDAQ:TELO

Telomir Pharmaceuticals 8/13/2024 Earnings Report

Telomir Pharmaceuticals logo
$1.29 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$1.26 -0.03 (-1.94%)
As of 05/22/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Telomir Pharmaceuticals EPS Results

Actual EPS
-$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Telomir Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Telomir Pharmaceuticals Announcement Details

Quarter
Date
8/13/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Telomir Pharmaceuticals Earnings Headlines

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease
May 20, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/32948/telomir-pharmaceuticals-reports-peer-reviewed-publication-of-telomir-zn-data-demonstrating-improved-survival-and-multiple-endpoint-benefits-in-wilsons-disease/
Telomir-Zn Preclinical Data Published in Wilson’s Disease
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-zn-preclinical-data-published-in-wilsons-disease?utm_source=marketbeat.com&utm_medium=referral
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
May 26 at 1:00 AM  |  Porter & Company (Ad)
Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn
April 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-receives-fda-ind-clearance-for-telomir-zn?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
April 24, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/31216/telomir-pharmaceuticals-completes-acquisition-of-teli-pharmaceuticals-securing-global-rights-to-telomir-1-telomir-zn/
Telomir Pharmaceuticals Inc.
April 2, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/telo/research-ratings
See More Telomir Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Telomir Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telomir Pharmaceuticals and other key companies, straight to your email.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals (NASDAQ:TELO) (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling. In parallel, Telomir maintains a preclinical pipeline of compounds designed to act on distinct molecular targets with the goal of delivering differentiated safety and efficacy profiles. Collaborative partnerships with academic institutions and contract research organizations support translational research efforts and accelerate compound progression from discovery through early clinical evaluation.

Headquartered in the United States, Telomir Pharmaceuticals is guided by an executive team with extensive experience in biopharmaceutical research, clinical development and regulatory affairs. While the company’s initial focus is on advancing its lead programs through clinical milestones in North America, management has articulated plans to pursue strategic alliances that could enable broader international development and commercialization. As a Nasdaq-listed entity, Telomir continues to refine its pipeline and expand its scientific platform with the goal of delivering innovative therapies to patients around the world.

View Telomir Pharmaceuticals Profile
Earnings Tools